Hisamitsu Announces U.S. Launch of its “Fentanyl Transdermal System” for the Management of Chronic Pain

Hisamitsu Pharmaceutical Co., Inc. announces that on March 24, 2010  Apotex Corp.of Florida launched Hisamitsu Pharmaceutical’s “Fentanyl Transdermal System” for the management of chronic pain, which was approved by the U.S. Food and Drug Administration (FDA) on October 16, 2009. 

Hisamitsu Pharmaceutical transferred the business of the Fentanyl Transdermal System to its indirect wholly-owned subsidiary, Noven Pharmaceuticals, Inc, on December 31, 2009, and Apotex distributes the drug exclusively in the U.S. Through the distribution of the Fentanyl Transdermal System, Hisamitsu and Apotex will provide patients who suffer from chronic pain with a high quality treatment option for the improvement of Quality of Life. 

About Fentanyl Transdermal System

The Fentanyl Transdermal System, developed by Hisamitsu, is a 72-hour matrix type transdermal patch containing Fentanyl, indicated for
management of persistent moderate to severe pain. Annual sales for the total transdermal Fentanyl patch market in the U.S. (the targeted market
for Hisamitsu’s Fentanyl Transdermal System) were approximately $1.1 billion in 2009.